The arrival of amivantamab represents a exciting step forward for people battling cancers with c-MET overexpression. This innovative therapeutic, a targeted blocker of both MET kinase plus human epidermal growth factor https://cormacvhbt007375.wikimidpoint.com/7071657/amivantamab_a_potential_solution_for_c_met_driven_growths